Cases & Deals

  • Home
  • Practices
  • Celgene develops global patent portfolio for agonistic anti-PD1 antibody therapeutics

Share

Celgene develops global patent portfolio for agonistic anti-PD1 antibody therapeutics

September 2016

Client(s) Celgene Corporation

Jones Day represents Celgene Corporation in the establishment of a global patent portfolio related to agonistic anti-PD1 therapeutic antibodies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.